Clinical trials: Residual
Lung Neoplasms
Pulmonary Ventilation/Perfusion Imaging for the Prediction of Postoperative Residual Pulmonary Function
Lung cancer is one of the most common malignant tumors in the world and with the highest incidence in China. Surgery is the most effective therapeutic method for primary lung cancer.
- Trial name
- NCT03357094
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Beijing Tongren Hospital
End Stage Renal Disease on Dialysis
Diuretic Use in Hemodialysis Patients With Residual Renal Function
This pilot trial will evaluate the use of diuretic medications (furosemide and chlorthalidone) in participants on dialysis to see if these medications work to preserve existing kidney function, increase urine output, and reduce…
- Trial name
- DIURESED (NCT05915286)
- Testing
- Furosemide, Chlorthalidone
- Where
- Canada
- Volunteers
- 2 people
- Sponsor
- University of Alberta
Malaria Transmission, Malaria Prevention
Long-acting Spatial Emanators / Repellents (LASER)
Malaria is a major problem in western Kenya, particularly around Lake Victoria. Whilst current prevention methods like bed nets and vaccines help to reduce malaria burden, additional tools are needed to better protect communities…
- Conditions
- Malaria Transmission, Malaria Prevention, Malaria
- Trial name
- LASER (NCT07387341)
- Testing
- Guardian, IRS with Pirimiphos - methyl
- Where
- Kenya
- Volunteers
- 22,815 people, healthy volunteers welcome
- Sponsor
- Liverpool School of Tropical Medicine
Cognitive Rehabilitation, Brain Injuries
Hypnosis in Working Memory Rehabilitation
Establishment of effective, efficient, and evidence-based interventions in rehabilitation of working memory (WM) deficits after acquired brain injury (ABI) is sorely needed.
- Conditions
- Cognitive Rehabilitation, Brain Injuries, Cognitive Impairment, Working Memory
- Trial name
- NCT05287542
- Testing
- Hypnotic suggestion, Mindfulness
- Where
- Norway
- Volunteers
- 90 people
- Sponsor
- Sunnaas Rehabilitation Hospital
Speech Sound Disorder
Intensive Speech Motor Chaining Treatment for Residual Speech Sound Disorders
The goal of this randomized-controlled trial is to compare distributed treatment schedules and intensive treatment schedules in 84 school-age children with residual speech sound disorders.
- Trial name
- iChain (NCT05929859)
- Testing
- Speech Motor Chaining
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Syracuse University
Brain Injury Traumatic Mild, Concussion, Brain
Dual-task Assessment and Rehabilitation for Individuals With Residual Symptoms After mTBI
This research aims to develop an intervention that combines mTBI-specific motor and cognitive challenges into a progressive and challenging rehabilitation program.
- Trial name
- NCT03478059
- Testing
- Cognitive and Motor Dual-task Intervention
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Allina Health System
Recurrent Tuberculosis
Vitamin D to Resolve Inflammation After Tuberculosis (ResolveD-TB)
This Strategic Research Project is a translational proof-of-concept study that will determine whether vitamin D3 has potential to prevent recurrent tuberculosis (TB), as indicated by enhanced resolution of pulmonary inflammation…
- Trial name
- ResolveD-TB (NCT03011580)
- Testing
- Fultium-D3
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- Queen Mary University of London
Leukemia
Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia in Partial Remission or Complete Remission
RATIONALE: Monoclonal antibodies, such as alemtuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00458523
- Testing
- alemtuzumab, fluorescence in situ hybridization, mutation analysis
- Where
- 2 sites in United Kingdom
- Volunteers
- 54 people
- Sponsor
- Leeds Cancer Centre at St. James's University Hospital
T-cell Acute Lymphoblastic Leukemia
Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
In this study, the investigators are hypothesizing that daratumumab-hyaluronidase will effectively treat T-ALL in patients who have persistent or recurrent MRD following treatment with chemotherapy.
- Trial name
- NCT05289687
- Testing
- Daratumumab / Hyaluronidase Injection
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Eastern Cooperative Oncology Group
MRD-positive, Acute Lymphoblastic Leukemia
Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor（CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL
To evaluate the safety and efficacy of CD19/CD22 Bispecific chimeric antigen receptor (CAR)-T for the treatment of measurable residual disaese (MRD)-positive B cell acute lymphoblastic leukemia.
- Trial name
- NCT03919526
- Testing
- anti-CD19/CD22 CAR-T cells, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Breast Cancer, Lymph Node Metastasis
Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer
The purpose of this study is to determine how circulating tumor DNA (ctDNA), a sign of minimal residual disease (MRD), is detectable after surgery in patients with early HR+/HER2- breast cancer that has spread to 1-3 lymph nodes.
- Trial name
- NCT07025785
- Testing
- Circulating tumor DNA
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Leukemia
Imatinib Mesylate With or Without Hydroxychloroquine in Treating Patients With Chronic Myeloid Leukemia
RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as hydroxychloroquine, may stimulate the immune system in different ways and stop…
- Trial name
- NCT01227135
- Testing
- hydroxychloroquine, imatinib mesylate, cytogenetic analysis
- Where
- 3 sites in United Kingdom
- Volunteers
- 66 people
- Sponsor
- Lynn McMahon
CML (Chronic Myelogenous Leukemia
IIT PH1 KDS-1001 in Patients With CML
This open label, non-randomized, prospective phase I study is designed to evaluate if the addition of natural killer cell therapy (KDS-1001) to tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) patients with…
- Trial name
- NCT04808115
- Testing
- KDS-1001
- Sponsor
- Duke University
Diabetes Mellitus, Type 2
Digital Therapeutic Based Investigation to Improve Glycemic Control in Patients With Type 2 Diabetes and Residual Hyperglycemia on Stable Medical Therapy
Randomized, controlled, multicenter, pragmatic, pivotal trial with open-label extension evaluating the hypothesis that BT-001 an investigational digital therapeutic intended to help patients with type 2 diabetes improve their…
- Trial name
- BRIGHT (NCT05266625)
- Testing
- BT-001, Control App
- Where
- 3 sites in United States
- Volunteers
- 500 people
- Sponsor
- Better Therapeutics
Type 1 Diabetes, Insulin Dependent Diabetes
Evaluation of Vildagliptin (Galvus®) as add-on to Insulin in New-onset Type 1 Diabetes Mellitus
The primary objective of this study is to evaluate the action of DPP-IV inhibitors in the prevention of progressive beta cell dysfunction in patients with type 1 diabetes mellitus newly diagnosis ( less than 6 months).
- Conditions
- Type 1 Diabetes, Insulin Dependent Diabetes, Juvenile Onset Diabetes Mellitus, Autoimmune Diabetes
- Trial name
- NCT01559025
- Testing
- Vildagliptin
- Where
- Brazil
- Volunteers
- 44 people
- Sponsor
- Federal University of São Paulo
Residual Neuromuscular Blockade
Cardiac Output and Recovery Time
The purpose of this research is to determine the time it takes to reverse the effects of the intraoperative medication given to relax the muscles and how this period of recovery correlates with a function of the heart.
- Trial name
- NCT04619225
- Testing
- TetraGraph
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Mayo Clinic
Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer
Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer
The purpose of this study is to determine the safety as well as the most effective dose of the alpha-lactalbumin vaccine (aLA breast cancer vaccine) to treat patients with non-metastatic triple negative breast cancer…
- Conditions
- Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Residual Disease
- Trial name
- NCT04674306
- Testing
- α-lactalbumin vaccine, Zymosan
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- George T. Budd
Excessive Sleepiness
Study to Evaluate Armodafinil Treatment in Improving Prefrontal Cortical Activation and Working Memory Performance
The primary objective of this study is to determine whether treatment with armodafinil will provide improvements in prefrontal cortical activation in patients with OSAHS (Obstructive Sleep Apnea/Hypopnea Syndrome) who have…
- Trial name
- NCT00711516
- Testing
- Armodafinil
- Where
- 9 sites in United States
- Volunteers
- 40 people
- Sponsor
- Cephalon
Acute Myeloid Leukemia (AML), Minimal Residual Disease
Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)
This is a phase I / II study. The purposes of this study are to: 1) find out what effects, good and/or bad, the combination of the experimental drug avelumab and the drug azacitidine has on people with AML and MRD, and 2) test if…
- Trial name
- NCT03699384
- Testing
- Azacitidine, Avelumab
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Leukemia, Myeloid
A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy
CC-90011-AML-002 is a Phase 1/2, open-label, multicenter study to assess the safety, tolerability, and preliminary efficacy of CC-90011 given concurrently with Venetoclax and Azacitidine.
- Trial name
- NCT04748848
- Testing
- CC-90011, Venetoclax, Azacitidine
- Where
- 17 sites in United States, Belgium and 2 more
- Volunteers
- 1 people
- Sponsor
- Celgene
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.